Lupus nephritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lupus nephritis}} | {{Lupus nephritis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}[[User:Okamal|Omer Kamal, M.D.]][mailto:okamal@bidmc.harvard.edu <nowiki>[2]</nowiki>] | ||
==Overview== | ==Overview== | ||
Secondary prevention strategies following systemic lupus erythematosus include using [[aspirin]], [[ACE inhibitor|ACE inhibitors]], and [[statins]] to reduce [[Atherosclerotic disease|atherosclerotic diseases]], and using [[Cancer screening|cancer screenings]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Latest revision as of 17:45, 20 July 2018
|
Lupus nephritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lupus nephritis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Lupus nephritis secondary prevention |
|
Risk calculators and risk factors for Lupus nephritis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.
Secondary Prevention
Aims of secondary prevention measures for SLE include:[1][2]
- Preventing glucocorticoid usage and using the minimum dosage to prevent osteonecrosis and osteoprosis side effects
- Decreasing atherosclerotic events in patients
- Low doses of aspirin
- ACE inhibitors
- Statins
- For prevention and/or early diagnosis of malignancies:
- Regular age-related specific cancer screening recommended for the general population
References
- ↑ Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
- ↑ Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.